FDA record shows earlier accelerated nod for mirvetuximab soravtansine-gynx, date unclear

The FDA's website lists two separate notices for mirvetuximab soravtansine-gynx in FRα positive, platinum-resistant gynecologic cancers. One is titled FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer¹. The document reviewed for this notice does not include a specific date for this action.

The second notice confirms that on March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.²

A close reading of the two titles shows a small wording difference in the described indication. The accelerated approval notice refers to "peritoneal cancer," while the March 2024 full approval notice specifies "primary peritoneal cancer." It is not clear from the documents whether this reflects a change in the approved population or simply a difference in how each notice titled the same indication.

Based on the available records, an accelerated approval preceded the March 2024 action, consistent with FDA's accelerated approval pathway, which typically requires confirmatory evidence before conversion to full approval. However, the exact date of the earlier accelerated approval is not stated in the document reviewed, so it cannot be confirmed whether it occurred earlier in 2024 or in a prior year. No additional details on dosing, trial data, or confirmatory trial results were included in either document reviewed for this report.